Alpha-synuclein PET Tracer
Diagnostic for Parkinson's Disease
Phase 1Active - First-in-human study
Key Facts
Indication
Diagnostic for Parkinson's Disease
Phase
Phase 1
Status
Active - First-in-human study
Company
About AC Immune
AC Immune's mission is to diagnose, treat, and prevent neurodegenerative diseases through a precision medicine approach. The company has achieved significant validation through high-value partnerships with major pharmaceutical firms like Takeda, Janssen, and Lilly, and its pipeline features promising Phase 2 candidates in Alzheimer's and Parkinson's disease. Its strategy balances internal R&D of first- and best-in-class candidates with strategic collaborations that provide non-dilutive funding and de-risk development.
View full company profile